EANS-News: Oxygen Biotherapeutics Inc. /

Oxygen Biotherapeutics Builds New Relationships for Dermacyte
Products and
Traumatic Brain Injury Clinical Trials

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Contracts/Marketing/Biotechnology

Subtitle: Oxygen Biotherapeutics Builds New Relationships for
Dermacyte Products and Traumatic Brain Injury Clinical Trials

Durham, NC (euro adhoc) - Press Release

Oxygen Biotherapeutics Inc.:

Oxygen Biotherapeutics Builds New Relationships for Dermacyte
Products and Traumatic Brain Injury Clinical Trials

DURHAM, NC — Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) announced
today that the Company has formalized working relationships with an
international cosmetic company and a site monitoring company.

The cosmetic company has agreed to evaluate the patented technology
underlying the Company´s non-prescription topical beauty care
products for potential use in a product line targeted for
retail-based channels of trade, including mass market retailers.

The site monitoring company has agreed to assist the Company as it
expands into India to initiate new sites for its Phase II-b clinical
trial, "A Randomized, Placebo-Controlled, Double-Blind, Single-Dose
Escalation Study to Evaluate the Safety and Tolerability of Oxycyte?
in Patients with Severe, Non-Penetrating Traumatic Brain Injury."

Terms of the agreements and identities of the companies involved were
not disclosed.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is developing medical and cosmetic
products that efficiently deliver oxygen to tissues in the body. The
company has developed a proprietary perfluorocarbon (PFC) therapeutic
oxygen carrier and liquid ventilation product called Oxycyte? that is
being formulated for both intravenous and topical delivery. In April,
the company launched its first cosmetic product, Dermacyte? Oxygen
Concentrate. In addition, the company is focused on
perfluorocarbon-based oxygen carriers for use in traumatic brain
injury, decompression sickness, personal care, and topical wound
healing. More information is available at www.oxybiomed.com or
www.buydermacyte.com.

Caution Regarding Forward-Looking Statements.

This news release contains certain forward-looking statements by the
company that involve risks and uncertainties and reflect the
company's judgment as of the date of this release. These statements
include those referring to the plans for the expansion of the
Dermacyte product line and the timing of the introduction of those
new products. The forward looking statements are subject to a number
of risks and uncertainties including matters beyond the company´s
control that could lead to delays in the new product introductions
and customer acceptance of these new products and other risks and
uncertainties as described in our filings with the Securities and
Exchange Commission, including in the current report on Form 8-K on
May 4, 2010. Furthermore, there can be no assurance that such plans
will lead to meaningful sales of Dermacyte or generate any revenue
for the company. The company disclaims any intent or obligation to
update these forward-looking statements beyond the date of this
release. This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.

DURHAM, NC — Mai 19, 2010

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Oxygen Biotherapeutics Inc.
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Ellen Corliss

Vice President, Corporate Communications

& Investor Relations

Oxygen Biotherapeutics, Inc

2530 Meridian Pkwy, 3rd floor

Durham, NC 27713

Direct Telephone: +1 919 806 4405

Direct Fax: +1 919 806 4417

Email: e.corliss@oxybiomed.com

Branche: Biotechnology
ISIN: US69207P2092
WKN: A0YD9Z
Börsen: New York / Nasdaq